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Background: Sulfate is important for fetal growth and development. During pregnancy, the fetus relies on sulfate
from the maternal circulation. We report reference intervals for maternal plasma sulfate levels and fractional
excretion index (FEI) for sulfate in pregnancy, as well as sulfate levels in cord blood from term pregnancies.
Methods: Plasma and urine were collected from 103 pregnant women of 10-20 weeks gestation and 106 pregnant
women of 30-37 weeks gestation. Venous cord plasma was collected from 80 healthy term babies. Sulfate levels
were measured by ion chromatography. Plasma and urinary creatinine levels were used to calculate FEI sulfate in
pregnant women. Analyses provide reference intervals, and explored the relationship between maternal sulfate data
with several prenatal factors.
Results: Median maternal plasma sulfate levels were 452 μmol/L and 502 μmol/L at 10-20 and 30-37 weeks gestation,
respectively, and inversely correlated with FEI sulfate median values of 0.15 and 0.11. Overall reference intervals were
305-710 and 335-701 μmol/L (2.5th; 97.5th percentile; for 10-20 and 30-37 weeks gestation, respectively) for maternal
plasma sulfate, and 0.06-0.31 and 0.05-0.28 for maternal FEI sulfate. Term venous cord plasma sulfate median levels were
significantly (p = 0.038) higher in female babies (375 μmol/L) when compared to male babies (342 μmol/L), with an
overall reference interval of 175-603 μmol/L.
Conclusions: We provide the first reference intervals for maternal plasma sulfate levels and FEI sulfate, as well
as cord plasma sulfate levels. These findings provide reference data for further studies of sulfate levels in both
mother and child.
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Nutrient sulfate is the fourth most abundant anion in
human circulation (approximately 300 μmol/L) and has
numerous roles in human physiology [1,2]. Sulfate con-
jugation (sulfonation) of glycosaminoglycans such as
cerebroside sulfate and heparan sulfate, contributes to
the normal structure and function of tissues [3,4]. Sul-
fonation also detoxifies xenobiotics and certain pharma-
cological drugs such as acetaminophen [5,6], and in
most cases inactivates steroids and iodothyronines [7-9].
In addition, sulfate transforms the biological activity of
bile acids and catecholamines [10,11].* Correspondence: paul.dawson@mater.uq.edu.au
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unless otherwise stated.More than 20 genes involved in maintaining the re-
quired biological ratio of sulfonated and unconjugated
molecules have been linked to pathophysiologies in
humans and animals [12]. For example, genes encoding
sulfatases, which mediate the removal of sulfate from
proteoglycans or lipids, are linked to several lysosomal
storage diseases, including metachromatic leukodystro-
phy, Maroteaux-Lamy syndrome, Morquio A syndrome,
Sanfilippo A and D syndromes and Hunter syndrome
[13]. In addition, the SLC26A2 gene which mediates sul-
fate transport into chondrocytes for the sulfonation of
chondroitin proteoglycan, is linked to four types of
chondrodysplasias: multiple epiphyseal dysplasia (MEM),
diastrophic dysplasia (DTD), atelosteogenesis Type II
(AO2) and achondrogenesis Type IB (ACG1B) [14].l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ing intracellular sulfonation capacity. In adults and chil-
dren, a well-balanced diet contributes approximately one
third of body sulfate requirements (2.1-15.8 mmol/day)
[15-18]. The remaining two thirds of sulfate require-
ments are derived from the intra-cellular metabolism of
thiol compounds and the sulfur-containing amino acids
methionine and cysteine [19,20].
The developing human fetus has negligible capacity to
generate its own sulfate requirements, and thereby is re-
liant on sulfate supply from the maternal circulation via
the placenta [21]. Sulfate transport through the placenta
is mediated by the SLC13A4 sulfate transporter, which is
abundantly expressed in the syncytiotrophoblast layer of
the human and mouse placentae [22,23]. A related sul-
fate transporter, SLC13A1, is expressed in the maternal
kidneys where it mediates sulfate reabsorption and
maintains circulating sulfate levels [24].
During mouse gestation, increased Slc13a1 gene ex-
pression in the maternal kidneys leads to increased renal
sulfate reabsorption and a two-fold increase in circulat-
ing sulfate levels in the pregnant mouse [25]. The in-
creased sulfate level in pregnant female mice is proposed
to provide a reservoir of sulfate for supplying the high
sulfate demands in the developing fetal tissues [12]. Tar-
geted disruption of the Slc13a1 gene in pregnant female
mice leads to maternal renal sulfate wasting and hypo-
sulfatemia, as well as fetal hyposulfatemia and mid-
gestational miscarriage [25]. More recently, we have
shown that loss of function mutations in the human
SLC13A1 gene lead to renal sulfate wasting and hyposul-
fatemia [26]. In addition, certain physiological conditions
(vitamin D depletion, hypokalaemia, metabolic acidosis)
and pharmacological drugs (NSAIDS, glucocorticoids)
are known to down-regulate SLC13A1 mRNA and pro-
tein expression [27]. Furthermore, dietary sulfate intake
is correlated to circulating sulfate levels in both humans
and rodents [28,29]. Collectively, these studies highlight
the genetic, physiological and dietary contributions to
modulation of circulating sulfate levels, which have po-
tential clinical relevance to fetal growth and develop-
ment in human gestation.
Despite its diverse and important roles in human physi-
ology, sulfate is not routinely measured in clinical settings.
Previous research studies have measured sulfate levels in
biological fluids from relatively small cohorts using a range
of methodologies, including barium-based turbidimetric as-
says, spectrophotometric benzidine precipitation methods
and anion chromatography [1]. However, the clinical utility
of those approaches for measuring sulfate have not been
validated and therefore reference intervals for plasma sul-
fate and urinary sulfate excretion are not available. Interest-
ingly, some research studies have indicated an increased
sulfatemia in pregnant women when compared to non-pregnant women [30]. These earlier human studies,
together with more recent animal research linking mater-
nal hyposulfatemia in pregnancy with mid-gestational
miscarriage [24,25], led us to establish validated tests for
measuring sulfate in human plasma and urine in clinical
settings [26], and to further investigate sulfate levels in
human gestation.
In this paper we report reference intervals for mater-
nal plasma sulfate levels and FEI sulfate in early and late
human gestation, as well as venous cord plasma sulfate
levels in term infants. Our data also considers the poten-
tial association of sulfate parameters with several pre-
natal factors, including maternal age, gestational age at
recruitment and birth, gravidity, parity, vitamin supple-
ments and gender of the fetus.
Methods
The research protocol was approved by the Mater
Health Services Human Research Ethics Committee. All
women gave their written informed consent prior to
their inclusion in the study. The eligibility criteria for
our study were pregnant women ≥18 years of age who
were attending for routine antenatal care at the Mater
Mothers’ Hospital. Exclusion criteria were women with
one or more of the following: maternal diabetes, hyper-
tensive disorders, substance use, multi-fetal gestation,
major congenital abnormality and fetal death. Gesta-
tional age at sample collection was based on best esti-
mate, using menstrual dates corroborated by ultrasound
or early gestation ultrasound. Maternal blood and urine
sampling was aligned with routine clinical assessment
visits within the antenatal clinic. Each spot urine sample
(no preservative added) was collected at approximately
the same time as a blood sample into a lithium heparin
plasma separator tube (PST). Venous cord blood sam-
pling (in K2EDTA) was aligned with routine collection
from healthy term (37-41 weeks) deliveries (altruistic
cord blood donors) at the Queensland Cord Blood Bank
At The Mater.
Plasma and urinary sulfate were measured by ion
chromatography with suppressed conductivity detection
using a Dionex ICS2000, as previously described [26].
The coefficient of variation for sulfate analysis is <5 %
for urine and < 7.5 % for plasma. Creatinine levels were
quantitated using a Vitros 5.1 FS chemistry analyzer.
Fractional excretion index (FEI) of sulfate was calculated
using the formula (plasma creatinine [μmol/L] x urine
sulfate [μmol/L]) / (urine creatinine [μmol/L] x plasma
sulfate [μmol/L]). All samples were analysed blinded to
operator.
The methodology for determination of the reference in-
tervals for plasma sulfate and FEI sulfate has been based
on the recommendations from the International Feder-
ation of Clinical Chemistry [31]. All primary reference
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allowing for reliable estimates of the 2.5th and 97.5th cen-
tiles. A non-parametric calculation has been used for cal-
culation of ranges due to non-normally distributed data,
and the difficulty in interpreting log-transformed values.
A two-way Kruskal Wallis analysis of variance has
been used to determine if there are significant differ-
ences in maternal plasma sulfate and FEI sulfate between
both gender of the baby (males versus females) and ges-
tational age at recruitment (10-20 weeks versus 30-37
weeks). Further analyses (Mann-Whitney U test) have
been carried out to determine if within each gestational
time period (10-20 weeks and 30-37 weeks) plasma
sulfate and FEI sulfate differs for gender of the baby.
To determine if there are significant differences in ma-
ternal plasma sulfate and FEI sulfate within each gesta-
tional age (10-20 weeks and 30-37 weeks) with selected
clinical parameters, various statistical approaches have
been employed. Spearman’s correlation coefficient was
used for gestational age at recruitment, gestational age at
birth, birth weight, birth weight z-score (adjusted for ges-
tational age and gender [32]), parity (grouped to 0, 1, 2, 3+)
and gravidity (grouped to 0, 1, 2, 3, 4, 5+) while a two-way
Kruskal-Wallis test was used for prenatal vitamin supple-
ments that contain ferrous sulfate. In addition, Spearman’s
correlation coefficients were used to determine if there are
significant differences in cord plasma sulfate levels with
maternal age and gestational age at birth.Table 1 Summary of participant numbers from the two mater
stratified according to gender of baby, gestational age at bir
Maternal plasm
Gestational age at sampling 10-20 wk
Gender of baby Male F
Gestational age at birtha
30wk + 0d 36wk + 6d 2 2
37wk + 0d 37wk + 6d 6 3
38wk + 0d 38wk + 6d 10 1
39wk + 0d 39wk + 6d 13 1
40wk + 0d 43wk + 6d 21 1









aThe gestational age at birth is shown as a range of weeks (wk) and days (d).
bGravidity (G) and parity (P) was obtained only from participants in the 2 cohorts co
weeks gestation.All analyses have been carried out in StataSE version
10.1 (StataCorp Pty Ltd, College Station, Texas), except
for two-way Kruskal Wallis that was performed in SPSS
version 15 (IBM Corporation, Armonk, New York). Stat-
istical significance is based on a two-tailed level of 0.05.
Results
In this study, we recruited two cohorts of 120 pregnant
women in early (10-20 weeks) and late (30-37 weeks) ges-
tation. The sample sizes were reduced to 103 and 106, re-
spectively, following exclusion criteria or withdrawal of
consent that occurred post recruitment. For FEI sulfate
calculations, the lack of urine sampling further reduced
the sample sizes to 101 (early gestation) and 105 (late ges-
tation). For cord plasma analyses, a sample size of 80 was
reached following exclusion criteria or insufficient plasma
volume for sulfate measurements. A summary of partici-
pant numbers in each sampling group stratified according
to gender of baby, gestational age at birth, gravidity and
parity, is shown in Table 1.
Maternal plasma sulfate levels and FEI sulfate in
pregnancy
The 95% reference intervals for maternal plasma sulfate
and FEI sulfate are shown in Table 2. Median plasma sul-
fate levels were significantly increased at 30-37 weeks ges-
tation (502 μmol/L, p = 0.006) when compared to levels at
10-20 weeks gestation (452 μmol/L) (Figure 1A-B, Tables 3nal gestational age groups and the cord plasma group
th, gravity and parity
a and urine Cord plasma
30-37wk 37-41 wk
emale Male Female Male Female
7 3 - -
4 4 4 0
2 8 10 17 26
6 15 10 9 14
8 24 21 4 6
9 13 11 - -
1 20 10 - -
12 11 - -
5 9 - -
8 7 - -
3 20 16 - -
3 23 18 - -
0 9 9 - -
6 5 - -
ntributing maternal plasma and urine samples at 10-20 and 30-37
Table 2 Reference intervals for maternal and cord plasma sulfate parameters
Gender baby N Lower bounda (90% CI)b Upper bounda (90% CI)b
Maternal plasma sulfate (μmol/L) 10-20 weeks gestation
All 103 305 (220, 327) 710 (651, 743)
Male 52 244 (220, 313) 695 (615, 716)
Female 51 316 (310, 336) 732 (661, 743)
Maternal plasma sulfate (μmol/L) 30-37 weeks gestation
All 106 335 (325, 344) 701 (667, 811)
Male 58 328 (325, 367) 699 (637, 721)
Female 48 338 (337, 344) 784 (672, 811)
Maternal FEI sulfate 10-20 weeks gestation
All 101 0.06 (0.05, 0.07) 0.31 (0.27, 0.39)
Male 51 0.06 (0.06, 0.07) 0.30 (0.26, 0.31)
Female 50 0.06 (0.05, 0.09) 0.37 (0.27, 0.39)
Maternal FEI sulfate 30-37 weeks gestation
All 105 0.05 (0.03, 0.05) 0.28 (0.22, 0.40)
Male 58 0.04 (0.03, 0.06) 0.38 (0.20, 0.40)
Female 47 0.04 (0.04, 0.05) 0.23 (0.20, 0.23)
Cord plasma sulfate (μmol/L) 37-41 weeks gestation
All 80 175 (159, 216) 603 (553, 683)
Male 34 159 (159, 216) 598 (505, 598)
Female 46 186 (180, 243) 669 (538, 683)
N: Sample size.
aLower and Upper bounds represent the 95% reference intervals.
b90% confidence intervals around each lower and upper bound are shown in parentheses.
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carrying a male or female fetus (Tables 3 and 4).
Median FEI sulfate values were significantly lower at 30-
37 weeks gestation (0.11, p < 0.001) when compared to
values at 10-20 weeks gestation (0.15) (Figure 1C-D,
Tables 3 and 4), and were inversely correlated to plasma
sulfate levels at 10-20 weeks gestation (rho = -0.335, p <
0.001) and 30-37 weeks gestation (rho = -0.281, p = 0.004),
respectively (Figures 1E-F). There was a significant inter-
action of gender and FEI sulfate when comparing 10-20
and 30-37 weeks gestation (p = 0.038) (Table 4, Additional
file 1: Figure S1), indicating a marked decline in maternal
FEI sulfate as pregnancy progressed when the fetus is
female.
Investigation of maternal plasma and urinary sulfate data
and prenatal factors
We performed analyses on the maternal plasma sulfate
and FEI sulfate data with several prenatal factors
(Table 5). No significant association was found for gesta-
tion at recruitment or birth, birth weight, birth weight z-
score and prenatal multi-vitamin supplements. Maternal
FEI sulfate values at 30-37 weeks gestation correlated
negatively with gravidity (rho = -0.289, p = 0.003) and
parity (rho = -0.281, p = 0.004).Term cord plasma sulfate levels
Reference intervals for term cord plasma sulfate are shown
in Table 2. Analysis of 80 samples showed a median plasma
sulfate level of 357 μmol/L (Table 3), with no significant
correlation to maternal age (range 24-42 years) or gesta-
tional age (range 37-41 weeks) (Table 6). However, median
plasma sulfate levels were significantly (p = 0.038) higher
for female babies (375 μmol/L, n = 46) when compared to
male babies (342 μmol/L, n = 34) (Tables 3 and 6).
Discussion
In this study, we report the first set of reference intervals
for plasma sulfate and FEI sulfate using a validated sul-
fate test and provide new evidence on the physiological
regulation of sulfate in pregnancy. Our data extend pre-
vious research findings that show human plasma sulfate
levels are increased in early pregnancy compared to
healthy males and non-pregnant females with peak
values occurring at 30-37 weeks gestation [1,30]. In a
previous study, we reported similar findings in mice
[25]. In addition, we noted a negative correlation of FEI
sulfate (i.e. increasing renal sulfate reabsorption) with gra-
vidity and parity at 30-37 weeks gestation, with a steeper
decline occurring in female babies when compared to
male babies. Our data suggest that the gender of the fetus
Figure 1 Plasma sulfate and FEI sulfate levels in pregnant women. (A-B) Plasma sulfate levels and (C-D) FEI sulfate levels in (A, C) early (10-20
weeks) and (B, D) late (30-37 weeks) gestation. Individual data and median (bar). (E-F) Maternal plasma sulfate levels inversely correlate to FEI
sulfate. Individual data and trend line for (E) early gestation, rho = -0.335, p < 0.001 and (F) late gestation, rho = -0.281, p = 0.004.
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absorption of sulfate in the maternal kidneys.
Several earlier studies using ion chromatography reported
plasma sulfate median levels of approximately 300 μmol/L
in adult males and non-pregnant females [1]. In the present
study, we found an approximate 1.5-fold increase (452
μmol/L) at 10-20 weeks gestation when compared to pub-
lished data on non-pregnant women, with median levels
peaking (502 μmol/L) at 30-37 weeks gestation. This in-
creased sulfatemia in pregnant women is remarkable and
suggests active up-regulation of plasma sulfate levels, as
many circulating analytes usually decrease slightly during
gestation as a result of changes in extracellular fluid volume
and renal function [33,34].
Similar increases in circulating sulfate levels have been
reported for pregnant mice, with a two-fold increase and
levels peaking in late gestation [25]. The increased sulfate-
mia in pregnant mice is due to increased expression of the
renal Slc13a1 sulfate transporter, which mediates sulfate
reabsorption in the maternal kidneys [25]. Disruption of
the Slc13a1 gene in pregnant mice leads to maternal and
fetal hyposulfatemia, as well as late gestational miscarriage[25]. These findings highlight the importance of Slc13a1
for maintaining high maternal sulfatemia, which supplies
the high fetal demands for sulfate throughout pregnancy.
We have linked loss of function mutations (R12X and
N174S) in the human SLC13A1 gene with renal sulfate
wasting and hyposulfatemia [26]. The nonsense R12X
variant led to complete loss of SLC13A1 function and
has an allelic frequency of 0.36% in the general popula-
tion, whereas the N174S variant led to partial loss of
function (60% decrease) and has an allelic frequency of
26.99% [35]. Genetic screening for these two variants
was not performed in the current study. However, the
relatively high frequency of N174S may be relevant to
the varying plasma sulfate levels and FEI sulfate found
in our two cohorts of pregnant women. Nonetheless,
our findings of increasing sulfatemia in pregnancy is
most likely due to enhanced SLC13A1-mediated sulfate
reabsorption in the maternal kidneys, as suggested by
the negative correlation between maternal plasma sulfate
levels and fractional urinary sulfate excretion.
Of great interest is the slightly higher cord venous
plasma sulfate level in female babies when compared to
Table 3 Descriptive statistics for maternal and cord plasma
sulfate parameters
Gender baby N Range Median IQR (25th–75th)
All 103 220-743 452 166 (381-547)
Male 52 220-716 457 173 (364-537)
Female 51 310-743 452 183 (403-586)
Maternal plasma sulfate (μmol/L) 30-37 weeks gestation
All 106 325-811 502 126 (439-565)
Male 58 325-721 490 101 (449-550)
Female 48 337-811 533 198 (407-605)
Maternal FEI sulfate 10-20 weeks gestation
All 101 0.05-0.39 0.15 0.08 (0.12-0.20)
Male 51 0.06-0.31 0.14 0.09 (0.11-0.20)
Female 50 0.05-0.39 0.16 0.09 (0.12-0.21)
Maternal FEI sulfate 30-37 weeks gestation
All 105 0.03-0.40 0.11 0.06 (0.09-0.15)
Male 58 0.03-0.40 0.13 0.07 (0.09-0.16)
Female 47 0.04-0.23 0.10 0.06 (0.08-0.14)
Cord plasma sulfate (μmol/L) 37-41 weeks gestation
All 80 159-683 357 131 (292-423)
Male 34 159-258 342 133 (258-391)
Female 46 180-683 375 128 (322-450)
N: Sample size; IQR: interquartile range, with lower (first) and upper (third)
quartile shown in parentheses.
Table 5 Analysis of maternal sulfate data and clinical
parameters
Clinical parameter Rhob *p-Value
Maternal plasma sulfate 10-20 weeks gestation
Gestational age at recruitment 0.004 -
Gestational age at birth 0.016 -
Birth weight 0.156 -
Birth weight z-scorea 0.103 -
Gravidity 0.019 -
Parity 0.041 -
Vitamin supplement - -
Maternal plasma sulfate 30-37 weeks gestation
Gestational age at recruitment 0.140 -
Gestational age at birth 0.147 -
Birth weight -0.047 -
Birth weight z-scorea -0.126 -
Gravidity 0.097 -
Parity 0.151 -
Vitamin supplement - -
Maternal FEI sulfate 10-20 weeks gestation
Gestational age at recruitment -0.082 -
Gestational age at birth 0.012 -
Birth weight -0.088 -
Birth weight z-scorea -0.043
Gravidity -0.094 -
Parity -0.013 -
Vitamin supplement - -
Maternal FEI sulfate 30-37 weeks gestation
Gestational age at recruitment -0.037 -
Gestational age at birth 0.115 -
Birth weight 0.090 -
Birth weight z-scorea 0.003 -
Gravidity -0.289 0.003
Parity -0.281 0.004
Vitamin supplement - -
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the fetus and therefore its composition reflects the
supply of analytes derived from the maternal circula-
tion. Accordingly, our data reflects a higher net sulfate
transport through the maternal-fetal barrier for female
babies when compared to males. The SLC13A4 sulfate
transporter is localised to the syncytiotrophoblast
layer of human placenta where it is proposed to be
mediating sulfate supply from mother to fetus [23].
Male and female babies have similar placental
SLC13A4 levels [23], suggesting that SLC13A4 is un-
likely to be the cause of higher plasma sulfate levels inTable 4 Comparison of plasma sulfate levels and FEI
sulfate between gender and gestational age at recruitment
Parameter Factor *p-Value
Plasma sulfate Gender -
Time (10-20 versus 30-37 weeks) 0.006
Interaction -
FEI sulfate Gender -
Time (10-20 versus 30-37 weeks) <0.001
Interaction 0.038
Comparison of gender, gestational age of maternal plasma and urine sampling
(Time), and both Gender and Time (Interaction) for plasma sulfate levels and
FEI sulfate. FEI: Fractional Excretion index. *Only values <0.05 are shown.
aAdjusted for gestational age and gender.
bRho: Spearman’s correlation coefficient.
*Only values <0.05 are shown.
Table 6 Analysis of cord plasma sulfate data and clinical
parameters
Clinical parameter Rhoa *p-Value
Cord plasma sulfate 37-41 weeks gestation
Maternal age -0.010 -
Gestational age at birth -0.107 -
Gender of baby - 0.038
aRho: Spearman’s correlation coefficient.
*Only values <0.05 are shown.
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another placental sulfate transporter, SLC26A2, is
more abundant in cytotrophoblasts of male babies
when compared to female babies [23]. This gender dif-
ference for placental SLC26A2 expression suggests a
higher sulfate requirement in cytotrophoblasts of male
babies, which may potentially limit sulfate supply to
the male fetus. In addition, the present study also
shows a more rapid decline in maternal FEI sulfate (i.e.
increasing renal sulfate reabsorption) during pregnancy
when the fetus is female. This latter finding may sug-
gest a maternal contribution to the increased cord
plasma sulfate levels for female babies.
Interestingly, we show a negative correlation for FEI
sulfate with gravidity and parity in the cohort of women
at 30-37 weeks gestation. This finding suggests that in-
creased sulfate reabsorption in late gestation (i.e. lower
FEI sulfate values) is more prevalent for those women
with the highest number of previous pregnancies and
births. This finding may be relevant to our animal stud-
ies that showed increased renal sulfate reabsorption in
late gestation is important for maintaining normal preg-
nancy and high fecundity [25]. Since the present study
excluded data from women when major congenital ab-
normality and fetal death occurred, we are unable to
determine whether high FEI sulfate and low plasma sul-
fate levels lead to perturbed fetal development and/or
fetal loss. However, that will be the next phase of our
work.
Further studies are warranted to explore the physio-
logical roles of sulfate in pregnancy; the differences ob-
served in FEI sulfate levels at 30-37 weeks gestation in
mothers with increasing gravidity and parity and female
infants; the gender differences noted in cord plasma sul-
fate levels; and whether low maternal sulfate levels lead
to perturbed fetal development.
Conclusions
We provide the first set of reference intervals for mater-
nal plasma sulfate and FEI sulfate in early and late gesta-
tion, and for term venous cord plasma sulfate, using a
validated sulfate test. Our findings show increased ma-
ternal plasma sulfate levels in pregnancy with levels
peaking within 30-37 weeks gestation. This increased
sulfatemia is inversely correlated to fractional urinary
sulfate excretion, indicating the contribution of the ma-
ternal kidneys to maintaining high circulating sulfate
levels in human gestation. Our data also show higher
term venous cord plasma sulfate levels for female babies
when compared to male babies. Collectively, this study
provides reference data for future clinical studies of sul-
fate levels in human gestation, and warrants investiga-
tion into the consequences of abnormal plasma sulfate
levels in mother and child.Additional file
Additional file 1: Figure S1. Relationship between median maternal
FEI sulfate, gender of fetus and gestational age. A significant interaction
(p=0.038) between gender suggests that as gestation progresses,
maternal renal sulfate reabsorption is higher when carrying a female
fetus.
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